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Abstract
Live-attenuated strains of simian immunodeficiency virus (SIV) routinely confer apparent sterilizing immunity against
pathogenic SIV challenge in rhesus macaques. Understanding the mechanisms of protection by live-attenuated SIV may
provide important insights into the immune responses needed for protection against HIV-1. Here we investigated the
development of antibodies that are functional against neutralization-resistant SIV challenge strains, and tested the
hypothesis that these antibodies are associated with protection. In the absence of detectable neutralizing antibodies, Env-
specific antibody-dependent cell-mediated cytotoxicity (ADCC) emerged by three weeks after inoculation with SIVDnef,
increased progressively over time, and was proportional to SIVDnef replication. Persistent infection with SIVDnef elicited
significantly higher ADCC titers than immunization with a non-persistent SIV strain that is limited to a single cycle of
infection. ADCC titers were higher against viruses matched to the vaccine strain in Env, but were measurable against viruses
expressing heterologous Env proteins. In two separate experiments, which took advantage of either the strain-specificity or
the time-dependent maturation of immunity to overcome complete protection against SIVmac251 challenge, measures of
ADCC activity were higher among the SIVDnef-inoculated macaques that remained uninfected than among those that
became infected. These observations show that features of the antibody response elicited by SIVDnef are consistent with
hallmarks of protection by live-attenuated SIV, and reveal an association between Env-specific antibodies that direct ADCC
and apparent sterilizing protection by SIVDnef.
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Introduction
The development of a vaccine against HIV-1 continues to be
hampered by our limited understanding of the types of immune
responses needed for protection. Although safety considerations
preclude the use of live-attenuated HIV-1 in people [1–5], live-
attenuated strains of simian immunodeficiency virus (SIV) afford
the most reliable protection achieved to date in non-human
primate models, often providing apparent sterilizing immunity
against closely related challenge viruses [6–9]. Thus, identifying
the immune responses that mediate protection by live-attenuated
SIV and understanding how to elicit them by vaccination may
provide important insights for the development of a safe and
effective HIV-1 vaccine [10].
Antibody, T cell, and innate immunity have evolved to operate
synergistically as an integrated system [11–13], and a combination
of these immune responses may be necessary for complete
protection by live-attenuated SIV. However, the efficacy of at
least one of these immune responses increases over time, since
animals challenged with pathogenic SIVmac251 months after
inoculation with live-attenuated SIV are protected from infection,
whereas animals challenged at early time points become infected
[7,8]. Although live-attenuated SIV elicits virus-specific T cells
[14–16], and the quality of these T cell responses may change over
time, the frequency of virus-specific CD8+ T cells declines after the
acute peak of live-attenuated SIV replication [17]. In contrast,
antibodies capable of neutralizing virus infectivity develop over
time through affinity maturation [18–21]. An essential role for the
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affinity maturation of antibody responses could account for the
time-dependent development of protection by live-attenuated SIV
[22]. However, SIVmac251 is inherently resistant to neutralization
[23], and antibodies capable of neutralizing this challenge virus
are typically undetectable among completely protected animals
[8,9]. We therefore reasoned that functions of antibodies other
than neutralization may contribute to protection by live-attenu-
ated SIV.
In addition to virus neutralization, the antiviral functions of
antibodies include complement fixation and numerous conse-
quences of Fc receptor crosslinking, such as ADCC [13,24–29].
Since ADCC represents a potential effector mechanism and a
proxy for other activities of the same antibodies, we developed a
novel assay for quantifying the ability of antibodies to direct
ADCC. This assay measures ADCC against virus-infected target
cells expressing native conformations of the viral envelope
glycoprotein (Env), and is therefore more physiologically relevant
than methods based on coating target cells with recombinant
gp120, gp140, or peptides [30–37]. We used this assay to
investigate the induction of antibodies with ADCC activity, and
to test the hypothesis that higher ADCC activity against cells
infected by the challenge virus is associated with protection. Our
results indicate that persistent infection with SIVDnef elicits Env-
specific ADCC titers that develop over time, are cross-reactive
with Env proteins expressed by heterologous SIV strains, are
proportional to vaccine strain replication, and are higher among
animals protected against SIVmac251 infection.
Results
Time-dependent maturation of antibody responses
Plasma samples collected at longitudinal time points after
inoculation with SIVmac239Dnef were tested for their ability to
neutralize SIVmac239 and to direct ADCC against SIVmac239-
infected cells. Only four of ten macaques developed neutralizing
antibody titers, and these were not detectable until thirteen weeks
after inoculation with SIVmac239Dnef (Figure 1A). In contrast,
ADCC titers were detectable in all animals just three weeks after
inoculation with SIVmac239Dnef (Figure 1B). These ADCC titers
were Env-specific, since none of the plasma samples had
detectable ADCC activity against target cells infected with
SHIVSF162P3, which expresses the Env protein of HIV-1SF162.
To quantify ADCC titers, we calculated the plasma dilution that
reduces the luciferase signal from virus-infected cells by 50%, and
to measure differences in the extent of target cell elimination over
all dilutions tested, we calculated values for the area under the
curve (AUC). By both measures, progressive increases in ADCC
were observed over 21 weeks. Thus, antibody titers capable of
directing ADCC against SIVmac239-infected cells increased over
time, but unlike neutralizing antibodies, emerged early and were
detectable in all animals.
Neutralizing antibodies were only detectable in the plasma
samples with high ADCC titers. A 50% ADCC titer of
approximately 104 emerged as a threshold, below which neutral-
ization of SIVmac239 was not detectable (Figure 1C). Among all of
the plasma samples collected after inoculation with SIVmac239
Dnef, the odds of detecting neutralization were 1,966-fold higher
per log10 increase in 50% ADCC titer (95% CI = 1.8 to 2,192,451,
P = 0.034), as estimated by logistic regression (Figure 1C).
Likewise, there was a trend towards a higher probability of
detecting neutralization by plasma with higher AUC values for
ADCC (odds ratio: 67,788-fold higher per 1 AUC unit, 95%
CI = 0.835–5.56109, P = 0.054) (Figure 1D). ADCC titers there-
fore predicted and were correlated with neutralization.
Persistent replication required to elicit high ADCC titers
The contribution of ongoing vaccine strain replication to the
development of antibody responses was evaluated by comparing
ADCC in animals immunized with SIVmac239Dnef to ADCC in
animals immunized with an SIV strain that is limited to a single
cycle of infection. Plasma samples collected two or twelve weeks
after a series of inoculations with single-cycle SIV [38] were tested
for ADCC against SIVmac239-infected cells (Figure 2A). Since the
geometric mean peak viral RNA loads in plasma for SIVmac239
Dnef and single-cycle SIV were within two-fold of each other,
1.36105 and 7.46104 copies per ml respectively (Figure 2B),
differences in antibody responses relate to differences in the
persistence of SIVmac239Dnef versus single-cycle SIV. Five weeks
after inoculation with SIVmac239Dnef, median 50% ADCC titers
were 51-fold higher than those elicited by single-cycle SIV, and
this difference expanded to 233-fold by week 21 (Figure 2C). The
50% ADCC titers (Figure 2C) and the AUC values for ADCC
(Figure 2D) at any time point after inoculation with SIVmac239Dnef
were significantly higher than at either time point after inoculation
with single-cycle SIV (2-tailed Mann-Whitney U tests, P = 0.0062
to P,0.0001). Thus, in contrast to persistent infection with
SIVmac239Dnef, repeated stimulation of antibody responses with
SIV limited to a single cycle of infection did not elicit high ADCC
titers.
ADCC titers measured after immunization with SIVmac239Dnef
and single-cycle SIV were compared with antibody titers that bind
recombinant forms of SIVmac239 Env in enzyme-linked immuno-
adsorbent assays (ELISAs). Relationships among these measures of
Env-specific antibody responses were evaluated by calculating
Spearman correlation coefficients (RS). ELISA titers against
SIVmac239 gp120 correlated with 50% ADCC titers against
SIVmac239-infected cells (RS = 0.8190, P,0.0001) (Figure 2E),
and with AUC values for ADCC (RS = 0.7809, P,0.0001)
(Figure 2F). Although a linear relationship was observed between
Author Summary
Live-attenuated vaccines can prevent simian immunode-
ficiency virus (SIV) infection upon experimental challenge
of rhesus macaques. Although safety considerations
preclude vaccinating humans with live-attenuated HIV-1,
it may be possible to replicate the types of immunity
induced by live-attenuated SIV through an alternative
approach. Thus, identifying the immune responses under-
lying protection by live-attenuated SIV and understanding
their induction would provide guidance for HIV-1 vaccine
design. An important role for the maturation of virus-
specific antibody responses could explain the time-
dependent development of protection by live-attenuated
SIV. However, antibodies that block the entry of the
challenge virus into cells are usually undetectable. Anti-
bodies can also direct the killing of virus-infected cells by
antibody-dependent cell-mediated cytotoxicity (ADCC).
Here we show that live-attenuated SIV induces progressive
increases in ADCC over time, and that the development of
these antibodies is dependent upon the persistent
replication of the vaccine strain. In two different experi-
ments, the animals immunized with live-attenuated SIV
that remained uninfected after pathogenic SIV challenge
had higher measures of ADCC than those that became
infected. Our results suggest that antibodies contribute to
protection by live-attenuated SIV, and that persistent
stimulation of antibody responses may be essential for
HIV-1 vaccines to induce high ADCC activity.
ADCC in Live-Attenuated SIV
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ADCC and gp120-binding titers in the animals persistently
infected with SIVmac239Dnef, plasma samples from the animals
immunized with single-cycle SIV belonged to an out-group, which
was displaced towards higher gp120-binding titers, relative to
ADCC (Figure 2E and F). ELISA titers against gp140 also
correlated with 50% ADCC titers (RS = 0.9015, P,0.0001)
(Figure 2G), and with AUC values for ADCC (RS = 0.8836,
P,0.0001) (Figure 2H). However, any displacement of the single-
cycle SIV-immunized animals towards higher gp140-binding,
relative to ADCC titers, was more subtle than that observed for
gp120-binding titers (Figure 2E–H). This may reflect the occlusion
of surfaces in gp140 oligomers that are exposed on gp120
monomers [39]. In comparison to persistent infection with
SIVmac239Dnef, immunization with single-cycle SIV may therefore
stimulate a higher proportion of gp120-specific antibodies with low
or undetectable ADCC activity against virus-infected cells, due to
recognition of epitopes that are occluded in the native Env trimer.
Recognition of heterologous Env proteins
The ADCC activity against SIV strains that were matched or
mismatched with the vaccine strain in Env was compared. Sera
were collected from twelve macaques inoculated with SIVmac239
Dnef (Figure 3A), and twelve inoculated with a recombinant form of
SIVmac239Dnef containing the env gene of SIVsmE543-3 [40],
designated SIVmac239Dnef/E543-3env (Figure 3B). Sera from all 24
animals were tested for ADCC activity against target cells infected
Figure 1. Development of neutralizing antibody and ADCC titers in macaques inoculated with SIVmac239Dnef. Plasma collected from
10 animals at 0, 3, 5, 7, 13 or 15, and 21 weeks after inoculation with SIVmac239Dnef was evaluated for its capacity to neutralize SIVmac239 (A) and to
direct ADCC against SIVmac239-infected cells (B). The loss of relative light units (RLU) indicates the loss of virus-infected cells during an 8-hour
incubation in the presence of plasma and an NK cell line. Target cells infected by SHIVSF162P3 served as a negative control for all ADCC assays (gray).
Dashed lines indicate 50% activity. Neutralizing antibody titers were compared with 50% ADCC titers (C), and with AUC values for ADCC (D). An odds
ratio (OR) for the probability of detecting neutralization per log10 increase in 50% ADCC titer, or per 1 AUC unit increase in ADCC activity, was
estimated by logistic regression.
doi:10.1371/journal.ppat.1002890.g001
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with SIVmac239 or SIVmac239/E543-3env. On average, the 50%
ADCC titers were seven-fold higher when the vaccine and test
viruses were matched in Env than when they were mismatched (2-
tailed Wilcoxon matched pairs test, P,0.0001). The 50% ADCC
titers were also approximately seven-fold higher at week 22 than at
week 6 (2-tailed Wilcoxon matched pairs test, P,0.0001). Thus, the
50% ADCC titers against the Env-matched virus at week 6 and the
Env-mismatched virus at week 22 were comparable. Therefore,
ADCC titers against Env-mismatched viruses were lower and
required more time to develop than ADCC titers against Env-
matched viruses.
ADCC activity is proportional to the extent of vaccine
strain replication
The extent of vaccine strain replication was estimated by
calculating AUC values for log10-transformed SIVDnef viral RNA
loads in plasma over the first 21 or 22 weeks after inoculation.
AUC values for viral loads among animals inoculated with
SIVmac239Dnef and SIVmac239Dnef/E543-3env were similar, aver-
aging 65 and 67 log10-transformed RNA copies per ml6weeks,
respectively. The extent of vaccine strain replication by the end of
this time period correlated with 50% ADCC titers against Env-
matched (RS = 0.68, P,0.0001) and Env-mismatched (RS = 0.55,
P = 0.006) viruses (Figure 4A), and also with AUC values for
ADCC against Env-matched (RS = 0.64, P,0.0001) and Env-
mismatched (RS = 0.42, P = 0.0421) viruses (Figure 4B). These
relationships suggest that the development of antibodies that direct
ADCC is driven by the extent of antigenic stimulation provided by
vaccine strain replication.
Higher ADCC among animals uninfected after SIVmac251
challenge
Twelve animals were challenged intravenously with SIVmac251NE
46 weeks after inoculation with SIVDnef. The SIVDnef strain in six of
these twelve animals was SIVmac239Dnef, whereas the other six were
inoculated with SIVmac239Dnef/E543-3env. All twelve of these
animals resisted two intravenous challenges with SIVmac239 on
weeks 22 and 33, while three naı¨ve control animals challenged on
Figure 2. ADCC titers elicited by SIVmac239Dnef versus single-cycle SIV. Plasma samples collected on weeks 2 and 12 after a series of
inoculations with single-cycle SIV were titered for ADCC against SIVmac239-infected cells (A). Target cells infected with SHIVSF162P3 served as a
negative control (gray). Dashed lines indicate 50% activity. Geometric mean vaccine strain viral loads reflecting virus particles produced in vivo after
inoculation with SIVmac239Dnef or single-cycle SIV are shown (B). Animals in Group A were inoculated 3 times with single-cycle SIV that was trans-
complemented with the vesicular stomatitis virus glycoprotein (VSV G), whereas the animals in Group B were inoculated 6 times with single-cycle SIV
that was not trans-complemented [38]. The 50% ADCC titers (C) and the AUC values for ADCC (D) elicited by SIVmac239Dnef were significantly higher
than those elicited by single-cycle SIV (2-tailed Mann-Whitney U tests, P = 0.0062 to P,0.0001). Binding titers measured by ELISA against SIVmac239
gp120 were correlated with 50% ADCC titers (E), and with AUC values for ADCC (F). Binding titers against SIVmac239 gp140 were also correlated with
50% ADCC titers (G), and with AUC values for ADCC (H).
doi:10.1371/journal.ppat.1002890.g002
ADCC in Live-Attenuated SIV
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week 22 and two challenged on week 33 all became infected. When
the twelve SIVDnef-immunized animals were subsequently re-
challenged with SIVmac251NE on week 46, three became infected,
as did both naı¨ve control animals challenged at the same time.
Although all three immunized animals that became infected were
among those inoculated with SIVmac239Dnef/E543-3env, the trend
toward more infections in this group was not significant (2-tailed
Fisher’s exact test, P = 0.18). Comparisons of SIVDnef viral loads for
animals that became infected versus remained uninfected, or animals
immunized with SIVmac239Dnef versus SIVmac239Dnef/E543-3env,
did not reveal significant differences (Figure S1A–D). Likewise, sera
collected on the day of challenge from the animals that remained
uninfected by SIVmac251NE did not have significantly higher binding
titers against gp120 (2-tailed Mann-Whitney U test, P = 0.2091)
(Figure S1E), or gp140 (2-tailed Mann-Whitney U test, P = 0.3727)
(Figure S1F), in comparison to the animals that became infected.
Sera drawn the day of intravenous challenge with SIVmac251NE
were tested for neutralization of SIVmac251NE and for ADCC
against SIVmac251NE-infected cells. Neutralizing antibody titers
were low to undetectable (Figure 5A), and differences among the
infected versus uninfected animals were not significant at the
highest serum concentration tested, a 1:8 dilution (2-tailed Mann-
Whitney U test, P = 0.3727). However, all of these samples had
measureable ADCC activity (Figure 5B). Whereas differences in
50% ADCC titers were not significant (Figure 5C), the animals
that remained uninfected by SIVmac251NE had higher AUC values
for ADCC than those that became infected (2-tailed Mann-
Whitney U test, P = 0.0091) (Figure 5D). Thus, more complete
elimination of the SIVmac251NE-infected target cells, as measured
by AUC values for ADCC, was associated with protection against
infection by intravenous challenge with SIVmac251NE.
To address the temporal association between the development of
antibody responses and protective immunity, we studied animals
that were challenged at different time points after inoculation with
SIVmac239Dnef. Groups of six female macaques were challenged by
high-dose vaginal inoculation with SIVmac251UCD at weeks five,
twenty, or forty after immunization with SIVmac239Dnef (Reeves et
Figure 3. ADCC against viruses matched or mismatched to the vaccine strain in Env. Sera drawn 0, 6, or 22 weeks after inoculation with
SIVmac239Dnef (A) or with the recombinant vaccine strain SIVmac239Dnef/E543-3env (B) were tested for ADCC against target cells infected with
SIVmac239 (black), SIVmac239/E543-3env (green), or SHIVSF162P3 (gray). Dashed lines indicate 50% activity.
doi:10.1371/journal.ppat.1002890.g003
Figure 4. Relationship between the extent of vaccine strain
replication and ADCC activity. The extent of SIVmac239Dnef or
SIVmac239Dnef/E543-3env replication was estimated from the area
under the curve (AUC) of log10-transformed vaccine strain viral loads
over weeks 0 through 21 or 22, and compared to ADCC activity at week
21 or 22. Vaccine strain viral load AUC values were correlated with 50%
ADCC titers (A) against Env-matched (RS = 0.68, P,0.0001) and Env-
mismatched (RS = 0.55, P = 0.006) SIV strains, and also with AUC values
for ADCC activity (B) against Env-matched (RS = 0.64, P,0.0001) and
Env-mismatched (RS = 0.42, P = 0.0421) SIV strains. Linear regression
lines are drawn.
doi:10.1371/journal.ppat.1002890.g004
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al., manuscript in preparation). All six animals challenged at week
five became infected, as did three of six animals challenged at week
twenty, and four of six animals challenged at week forty. Three
naı¨ve control animals challenged at each time point all became
infected, except one animal challenged at week twenty. Peak
SIVmac239Dnef viral loads were unrelated to the outcome of
challenge (Figure S2A). Although the total extent of vaccine strain
replication, as estimated from AUC values for SIVmac239Dnef viral
loads, tended to be higher among the animals that remained
uninfected compared to those that became infected, this trend was
not significant (2-tailed Mann-Whitney U test, P = 0.0939) (Figure
S2B). The animals that remained uninfected by SIVmac251UCD also
did not have significantly higher binding antibody titers than those
that became infected, as measured by ELISA against gp120 (2-tailed
Mann-Whitney U test, P = 0.4304) (Figure S2C) or gp140 (2-tailed
Mann-Whitney U test, P = 0.1148) (Figure S2D).
Sera collected on the day of challenge with SIVmac251UCD were
evaluated for neutralization of SIVmac251UCD (Figure 6A–C).
However, neutralization of SIVmac251UCD was not detectable for
any of these serum samples (Figure 6A–C). The absence of
detectable neutralizing antibodies is a consequence of the inherent
resistance of SIVmac251UCD to neutralization (Figure S3). Indeed,
SIVmac251UCD is even more resistant to neutralization than
SIVmac251NE by plasma from animals chronically infected with
SIVmac239 (2-tailed Wilcoxon matched pairs test, P = 0.0098)
(Figure S3A), and by soluble CD4 (Figure S3B). The relative
resistance of SIVmac251UCD to antibody may have been a factor in
the small number of animals that were protected against infection
with this challenge strain.
The capacity of the same sera to direct ADCC against
SIVmac251UCD-infected cells was evaluated (Figure 6D–F). In
contrast to neutralization, all had measurable ADCC activity
(Figure 6D–F). Statistically significant outcomes could not be
reached at individual time points, or for a group of animals that
combines just those challenged on weeks twenty and forty (Table
S1). However, when the animals challenged five, twenty and forty
weeks after inoculation with SIVmac239Dnef were analyzed
together, those that remained uninfected had higher 50% ADCC
titers on the day they were challenged than those that became
infected (2-tailed Mann-Whitney U test, P = 0.0487) (Figure 6G).
A similar trend was observed for AUC values for ADCC, although
these differences were not significant (Figure 6H). Also, among the
animals that became infected, there was a trend towards higher
ADCC activity in animals with lower peak SIVmac251UCD viral
loads (Figure 6I and J). Therefore, higher 50% ADCC titers
present at later challenge time points after inoculation with
SIVmac239Dnef were associated with protection against infection
by high-dose vaginal challenge with SIVmac251UCD.
Discussion
Identifying the immune responses that mediate protection by
live-attenuated SIV and understanding their induction may inspire
strategies for engineering a safe and effective vaccine against HIV-
1. We hypothesized that antibody functions other than neutral-
ization contribute to the protective immunity provided by live-
attenuated SIV against wild-type pathogenic SIV challenge. Here
we demonstrate that properties of the antibody response reflected
Figure 5. Neutralization and ADCC on the day of intravenous challenge with SIVmac251NE. Macaques were challenged with an
intravenous dose of SIVmac251NE on week 46 after inoculation with SIVmac239Dnef or SIVmac239Dnef/E543-3env. Sera collected the day of challenge
were evaluated for neutralization of SIVmac251NE (A) and ADCC against SIVmac251NE-infected cells (B). Solid black symbols indicate animals that
became infected by SIVmac251NE. Dashed lines indicate 50% activity. Target cells infected with SHIVSF162P3 served as a negative control for ADCC
assays (gray). Differences in 50% ADCC titers were not significant (C). However, AUC values for ADCC were higher among the immunized animals that
remained uninfected versus the immunized animals that became infected (2-tailed Mann-Whitney U test, P = 0.0091) (D). None of these macaques
had the MHC class I alleles Mamu-A*01, -B*08 or -B*17 associated with reduced viral replication [67–69].
doi:10.1371/journal.ppat.1002890.g005
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in ADCC titers mirror hallmarks of protection by live-attenuated
SIV. The protective immunity conferred by live-attenuated SIV
increases over time [7,8], is usually incomplete against heterolo-
gous challenge [41,42], and is greater for vaccine strains that
replicate at higher levels [7,9]. In accordance with these
observations, our data indicate that ADCC titers increase
progressively over time, are lower against viruses expressing
heterologous Env proteins, and are proportional to the extent of
vaccine strain replication. Furthermore, in two different challenge
experiments, measures of ADCC activity were associated with
protection against infection by SIVmac251.
In one experiment, macaques inoculated with SIVmac239Dnef or
SIVmac239Dnef/E543-3env that remained uninfected after intrave-
nous challenge with SIVmac251NE had higher AUC values for
ADCC than those that became infected. In another experiment,
animals that remained uninfected after high-dose vaginal chal-
lenge with SIVmac251UCD at different time points after inoculation
with SIVmac239Dnef had higher 50% ADCC titers than those that
became infected. Differences in AUC values for ADCC were
significant in one experiment, whereas differences in 50% ADCC
titers were significant in the other, perhaps reflecting the limited
power to detect differences using small numbers of infected versus
uninfected animals. Additional differences between the two
studies, including the greater resistance of SIVmac251UCD than
SIVmac251NE to antibodies, the greater length of time allowed for
the maturation of antibody responses prior to challenge with
Figure 6. Neutralization and ADCC on the day of high-dose vaginal challenge with SIVmac251UCD. At 5, 20, or 40 weeks after inoculation
with SIVmac239Dnef, groups of 6 macaques each were challenged by high-dose vaginal inoculation with SIVmac251UCD. Serum collected the day of
challenge was evaluated for neutralization of SIVmac251UCD (A–C) and ADCC against SIVmac251UCD-infected cells (D–F). Symbols appear in color for
immunized macaques that remained uninfected by SIVmac251UCD, and in black for the immunized animals that became infected. Target cells infected
with SHIVSF162P3 served as a negative control for ADCC assays (gray). Dashed lines indicate 50% activity. The groups challenged on weeks 5, 20, and
40 were combined for statistical analysis (G–J). The SIVmac239Dnef-immunized macaques remaining uninfected by SIVmac251UCD had higher 50%
ADCC titers than those that became infected (2-tailed Mann-Whitney U test, P = 0.0487) (G). A similar but non-significant trend was observed in AUC
values for ADCC (2-tailed Mann-Whitney U test, P = 0.0761) (H). Non-significant trends were in the direction of lower peak SIVmac251UCD viral loads for
animals with higher 50% ADCC titers (RS =20.4615, P = 0.1124) (I) and higher AUC measurements of ADCC activity (RS =20.4560, P = 0.1173) (J).
Linear regression lines are shown. The macaque with the lowest ADCC titers among those remaining uninfected was the only animal possessing the
protective combination of MHC class I alleles Mamu-A*01 and -B*17 [70].
doi:10.1371/journal.ppat.1002890.g006
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SIVmac251NE (46 weeks) than SIVmac251UCD (5, 20, and 40
weeks), and the effect of mismatches in Env between SIVmac239
Dnef/E543-3env and SIVmac251NE, may also have contributed to
the detection of differences in AUC values for ADCC against
SIVmac251NE. Although differences between the two SIVmac251
challenge experiments may have favored one method of data
analysis over the other, measures of ADCC activity were
associated with complete protection in both experiments.
While the relationship between ADCC activity and the outcome
of challenge suggests that these antibodies contribute to protection,
correlation does not establish causation. In addition to ADCC, Fc
receptor crosslinking stimulates the secretion of molecules that
promote lymphocyte homing and activation, and that may inhibit
virus replication [26,27]. The antibodies that direct ADCC may
also mediate effector functions through complement fixation
[25,28]. Furthermore, ADCC assays may measure antibodies that
block virus infection at concentrations present in vivo, but are
undetectable using conventional neutralization assays. Therefore,
although ADCC may be an important effector mechanism [43],
ADCC could also be a surrogate for other effector mechanisms
that contribute to protection. Mechanisms of immunity not
mediated by antibodies may also covary with ADCC activity.
For instance, T cell, antibody, and innate immune responses may
all be affected by the extent of antigenic stimulation. It is
conceivable that the observed relationships are due to differences
that exist among animals inoculated with SIVmac239Dnef versus
SIVmac239Dnef/E543-3env, or among animals challenged five,
twenty, and forty weeks after inoculation with SIVmac239Dnef.
Thus, while our findings implicate antibodies in protection by live-
attenuated SIV, they do not preclude a role for other immune
responses.
More than one type of immune response elicited by live-
attenuated SIV may be necessary for complete protection against
SIVmac251 challenge. Passive transfer experiments in different
live-attenuated SIV vaccine models have yielded mixed results
regarding the ability of antibodies alone to protect against SIV
infection, demonstrating complete protection in one study [44],
and no protection in another [45]. In contrast to the absence of
detectable neutralizing antibodies in the completely protected
animals in this study, relatively high concentrations of neutralizing
monoclonal antibodies were necessary to protect macaques against
SHIV infection in passive transfer experiments [43,46–48]. T cell
responses present in macaques inoculated with SIVDnef [14–16],
but absent in macaques that received antibodies passively, may
help to explain these differences in neutralizing antibody titers
required for complete protection.
Our observations are in agreement with other reports that have
associated antibody responses with protection. The Robert-Guroff
laboratory, and others, have associated lower viral loads after
infection with higher ADCC activity measured using target cells
that were coated with monomeric gp120 [32,36,37], recombinant
gp140 [33], or infected with T cell line-adapted SIV [49].
However, in these studies, ADCC was not associated with
protection from infection, or measured using target cells infected
with neutralization-resistant viruses. Nevertheless, antibodies that
bound recombinant forms of gp120 by ELISA and that
neutralized neutralization-sensitive SIV strains were associated
with a reduced rate of infection [37]. Consistent with these
observations on vaccine protection, a recent study on mother-to-
child transmission of HIV-1 found that the breast milk of mothers
whose newborns remained uninfected contained antibodies with
higher ADCC activity against gp120-coated target cells [50]. In
the context of vaccination with different live-attenuated strains of
SIV, antibody avidity was also associated with resistance to
infection and lower post-challenge viral loads after vaginal
challenge with SIVmac251NE [9]. Likewise, neutralization of
SIVmac251NE at a 1:4 dilution of serum was associated with
protection in a combined group of animals that remained
uninfected or strongly controlled SIVmac251NE viral loads [7].
Taken together, these studies support a role for antibodies in
protective immunity.
Interest in antibody functions other than neutralization has
recently increased as a result of the RV144 trial, in which a modest
reduction in the rate of HIV-1 infection was reported among
recipients of a recombinant canarypox vector prime and gp120
protein boost vaccine [51]. Virus-specific CD8+ T cell responses
were not measurably different between vaccinated and unvacci-
nated trial participants. Whereas antibodies capable of neutraliz-
ing primary HIV-1 isolates were also undetectable among
vaccinated individuals, gp120-binding titers were consistently
detectable by ELISA. Functions of antibodies other than
neutralization have therefore been postulated to potentially be
responsible for protection in the RV144 trial [52]. Among six
primary variables in the immune correlates analysis of the RV144
trial, IgG titers to the V2 region of gp120 were associated with
protection, whereas Env-specific IgA antibodies were associated
with a higher risk of infection [53]. There was also a non-
significant trend towards a lower risk of HIV-1 infection among
vaccine recipients with higher ADCC activity using the assay
described here. This relationship reached borderline statistical
significance after excluding subjects with Env-specific IgA in
plasma [53]. These observations further support a role for
antibodies in vaccine protection against immunodeficiency virus
infection.
Persistent expression of Env may be essential to elicit protective
antibody responses. The progressive increases in ADCC activity
over time, and the considerably higher ADCC activity elicited by
SIVmac239Dnef versus single-cycle SIV, imply that the persistent
antigenic stimulation provided by ongoing SIVmac239Dnef repli-
cation is important for the development of high ADCC titers.
Differences in the maturation of antibody responses may also
contribute to the better protection provided by SIVDnef in
comparison to single-cycle SIV [38]. Furthermore, a longer period
of persistent infection with SIVDnef was required for ADCC titers
against SIV strains expressing heterologous Env proteins to reach
the levels observed at an earlier time point against the Env-
matched strain. Persistent Env expression may therefore be
required to elicit antibodies with high and broadly reactive ADCC
activity against circulating HIV-1 strains with diverse neutraliza-
tion-resistant Env proteins.
A vaccine against HIV-1 must contend with a degree of
sequence variation that typically renders neutralizing sera
ineffective against heterologous HIV-1 strains isolated from other
people [19,54]. The Env proteins of SIVmac239 and SIVsmE543-3
differ in amino acid sequence by 18%, which approximates the
median difference between the Env proteins of individual HIV-1
isolates within a clade [54,55]. Therefore, the ADCC titers
observed against cells infected with neutralization-resistant Env-
mismatched target viruses suggest that antibodies may have
broader efficacy against heterologous HIV-1 isolates than is
generally revealed by neutralization assays.
In summary, we show that properties of the antibody response
elicited by SIVDnef mirror hallmarks of protection by live-
attenuated SIV, and that ADCC activity is associated with
apparent sterilizing protection against SIVmac251. These obser-
vations support a role for antibodies in protection by live-
attenuated SIV, despite the paradoxical absence of detectable
neutralizing antibody titers against the challenge virus in most fully
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protected animals. The temporal analyses of ADCC activity
against both Env-matched and Env-mismatched viruses, and the
significantly higher ADCC titers observed in SIVDnef-infected
animals than in animals repeatedly immunized with single-cycle
SIV, suggest that persistent Env expression may be necessary to
drive the maturation of high-titer, broadly reactive antibody
responses. Therefore, strategies designed to persistently stimulate
Env-specific antibodies may significantly improve the efficacy of
vaccines against HIV-1.
Materials and Methods
ADCC assay
Due to the variability and limited scalability of assays dependent
upon primary cells, we engineered a pair of cell lines to serve as
targets and effectors in ADCC assays. The target cells were
derived from CEM.NKR-CCR5 CD4+ T cells [56,57] (AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH, contributed by Dr. Alexandra Trkola). These were
transduced with a pLNSX-derived retroviral vector to express
firefly luciferase under the transcriptional regulation of the SIV
LTR promoter [23]. Target cells were maintained in ‘‘R10’’ cell
culture media consisting of RPMI (Invitrogen) supplemented with
10% fetal bovine serum (FBS) (Invitrogen), 25 mM HEPES
(Invitrogen), 2 mM L-glutamine (Invitrogen), and 0.1 mg/ml
Primocin (InvivoGen). Effector cells were derived from the
CD16-negative human NK cell line KHYG-1 [58] (Japan Health
Sciences Foundation) by stable transduction with a pQCXIN-
derived retroviral vector expressing rhesus macaque CD16
(FCGR3A variant 7) [59]. KHYG-1 effector cells were maintained
at a density of 16105 to 46105 cells per ml in R10 media
supplemented with IL-2 at 10 U per ml (Roche) and cyclosporine
A at 1 mg per ml (Sigma).
Four days prior to each ADCC assay, the target cells were
infected by spinoculation [60]. On the day of the assay, infected
target cells were washed three times with R10 immediately before
use. ADCC assays were conducted in round-bottom 96-well plates.
Each well contained 105 effector cells and 104 target cells. Effector
and target cells were incubated together for eight hours in the
presence of triplicate serial two-fold dilutions of serum or plasma
before the luciferase activity was measured using the luciferase
substrate reagent BriteLite Plus (Perkin Elmer). Relative light units
(RLU) indicate luciferase expression by infected target cells. Wells
containing uninfected target cells plus effector cells defined 0%
RLU, and wells containing infected target cells plus effector cells
with no serum or plasma defined 100% RLU. The %ADCC
activity was defined as 100 minus %RLU.
Antibodies from some macaques bound uninfected CEM.NKR-
CCR5 cells. To deplete these antibodies, 107 uninfected target
cells were resuspended in the sample and incubated for twenty
minutes at room temperature. This process was repeated twenty
times for the animals immunized with single-cycle SIV, and twelve
times for the animals in the Env-mismatch and vaginal challenge
studies.
Neutralization assays
Neutralization was measured as previously described [23,61].
The sensitivity of the virus neutralization assay was maximized by
minimizing the amount of virus input required to obtain a
consistent level of infected C8166-secreted alkaline phosphatase
(SEAP) reporter cells. These amounts were 0.5 ng p27 SIVmac239,
5 ng p27 SIVmac251NE, and 0.5 ng p27 SIVmac251UCD per well.
However, the resistance of SIVmac251NE, SIVmac251UCD, and
SIVmac251TCLA to neutralization by sCD4-IgG was evaluated
using 5 ng p27 per well for all 3 viruses. Each well contained
15,000 C8166-SEAP cells. Plasma or serum dilutions were pre-
incubated with virus for one hour at 37uC before adding C8166-
SEAP cells. After three days, SEAP activity was determined using
a luminescent assay (Applied Biosystems).
ELISAs
Recombinant 6-His tagged SIVmac239 gp120 or gp140 protein
(Immune Technology) diluted to 0.5 mg/ml in 0.1 M sodium
bicarbonate pH 9.5 was coated onto Maxisorb ELISA plates
(NUNC). Plates were blocked using PBS containing 0.5%
TWEEN-20 (Sigma) and 5% blotting-grade non-fat dry milk
(NFDM) blocker (BioRad). Antibody dilutions were made in PBS
containing 0.5% TWEEN-20 and 5% NFDM. Bound IgG was
detected using a horseradish peroxidase conjugated goat anti-
monkey/human IgG antibody (Santa Cruz Biotechnology). The
upper limit of a 95% confidence interval calculated using plasma
from 10 naı¨ve macaques diluted 1:100 served as the endpoint titer
[62].
Animals
The animals were Indian-origin rhesus macaques (Macaca
mulatta) housed in a biocontainment facility at the New England
Primate Research Center (NEPRC), and given care in accor-
dance with standards of the Association for Assessment and
Accreditation of Laboratory Animal Care and the Harvard
Medical School Animal Care and Use Committee. The animal
samples used here were collected under experimental protocols
approved by the Harvard Medical Area Standing Committee on
Animals, and conducted in accordance to the Guide for the Care and
Use of Laboratory Animals [63]. Additional analyses using these
animals will be published separately by R. C. Desrosiers and by
R. K. Reeves.
Viruses
The intravenous SIVmac239 challenge dose used on week 22
consisted of twenty animal-infectious doses of virus produced by
transfection of 293T cells. The week 33 intravenous challenge with
SIVmac239 contained ten animal-infectious doses of a rhesus
PBMC-derived virus stock used previously [38]. The intravenous
SIVmac251NE challenge was ten animal-infectious doses (32 pg
p27) of a rhesus PBMC stock prepared in February of 1991, used
in other studies [7–9]. Vaginal challenges consisted of two
inoculations on one day of 1 ml undiluted SIVmac251UCD [64]
(100 ng p27), prepared at the California National Primate
Research Center in June of 2004. Neutralization and ADCC
assays were done using SIVmac239 and SIVmac239/E543-3env
produced by transfection of 293T cells, and SIVmac251NE and
SIVmac251UCD expanded from the corresponding uncloned
challenge stocks in rhesus macaque PBMC. SHIVSF162P3 was also
expanded in rhesus PBMC (AIDS Research and Reference
Reagent Program, NIAID, NIH, contributed by Drs. Janet
Harouse, Cecilia Cheng-Mayer, Ranajit Pal and the DAIDS,
NIAID). The rhesus PBMC used to expand virus stocks were
depleted of CD8+ cells using Dynal anti-CD8 magnetic beads
(Invitrogen), activated with phytohemagglutinin (PHA) (Sigma),
and then cultured in IL-2 (Roche). SIVmac251TCLA was grown in
MT4 cells.
Plasma viral RNA load measurements
Challenge viruses were detected using primers specific for the nef
sequences of SIVmac239 or SIVmac251 within the deletion in
SIVmac239Dnef [65]. The primers specific for wild-type SIVmac239
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were GAATACTCCATGGAGAAACCCAGC and ATTGC-
CAATTTGTAACTCATTGTTCTTAG, and the labeled probe
had the sequence CTTTTGGCCTCACTGATACCCCTAC. To
reflect the polymorphic nature of the uncloned SIVmac251 virus
stocks, the primer set designed to amplify SIVmac251 contained
degenerate bases P and K, which mimic mixtures of C and T or A
and G, respectively (GlenResearch). The SIVmac251-specific
primers were GAATACPCCATGGAKAAACCCAGC and
TGCCAATTTGTAA(C,T,G)TCATTGPTCTTAGG, and the
SIVmac251-specific probe sequence was TAGAPGAGGAAGAT-
GATGACTTGKTAGGG. Complete or apparent sterilizing
protection was defined as the absence of detectable wild-type viral
RNA from plasma at every post-challenge time point using the
above primer/probe sets in a real-time RT-PCR assay with a
nominal threshold of detection of 10–30 copies of RNA per ml
[66].
Statistical analysis
Fifty percent titers were calculated as the dilution at which a line
connecting the values above and below 50% RLU would intercept
the 50% RLU line. AUC values for ADCC were calculated such
that they would be proportional to 50% ADCC titers, and
represent the areas between 100% RLU and the titration curves as
they appear in the figures. Whereas %ADCC, defined as 100%
minus %RLU, appears asymptotic as it approaches 100%,
minimum %RLU values are inversely proportional to 50%
ADCC titers. Therefore, AUC values for ADCC were calculated
from values for log10100 minus log10%RLU, which were summed
over all dilutions. This sum was multiplied by the log10-
transformed dilution factor of two to find an area. The ability of
ADCC activity to predict neutralization was evaluated by logistic
regression using SPSS (IBM). The statistical significance of other
comparisons was evaluated in Prism version 4.1b (GraphPad
Software) using 2-tailed Mann-Whitney U tests, 2-tailed Fisher’s
exact tests, 2-tailed Wilcoxon matched pairs tests, and Spearman
correlation coefficients.
Supporting Information
Figure S1 SIVDnef viral loads and ELISA titers among
animals challenged with SIVmac251NE. There were no
significant differences in vaccine strain viral loads among the
animals that became infected versus those that remained
uninfected after intravenous challenge with SIVmac251NE in terms
of peak log10 RNA copies per ml (2-tailed Mann-Whitney U test,
P = 0.8636) (A), or AUC log10 RNA copies per ml6weeks for the
period of weeks 0–46 after inoculation (2-tailed Mann-Whitney U
test, P = 0.2091) (B). SIVmac239Dnef and SIVmac239Dnef/E543-
3env did not differ significantly in peak vaccine strain viral loads (2-
tailed Mann-Whitney U test, P = 0.8182) (C), or in AUC values for
vaccine strain viral loads over weeks 0–46 (P = 0.9372) (D). The
outcome of challenge was not significantly related to binding
antibodies measured by ELISA against recombinant SIVmac239
gp120 (2-tailed Mann-Whitney U test, P = 0.2091) (E), or gp140
(2-tailed Mann-Whitney U test, P = 0.3727) (F).
(TIFF)
Figure S2 SIVmac239Dnef viral loads and ELISA titers
among animals challenged with SIVmac251UCD. Peak log10
SIVmac239Dnef viral loads appeared unrelated to protection
against infection by SIVmac251UCD (2-tailed Mann-Whitney U
test, P = 0.8437) (A). SIVmac239Dnef AUC log10 RNA copies per
ml6weeks for the period through the day of challenge with
SIVmac251UCD at 5, 20, or 40 weeks after inoculation appeared
higher among the animals that remained uninfected, but this
difference was not significant (2-tailed Mann-Whitney U test,
P = 0.0939) (B). The SIVmac239Dnef-immunized animals that
remained uninfected did not have significantly higher ELISA
titers in sera collected on the day of challenge than those that
became infected against SIVmac239 gp120 (2-tailed Mann-
Whitney U test, P = 0.4304) (C), or gp140 (2-tailed Mann-Whitney
U test, P = 0.1148) (D).
(TIFF)
Figure S3 Neutralization resistance of SIVmac251
strains. SIVmac251NE, SIVmac251UCD, and T cell line-adapted
SIVmac251TCLA were compared for their relative resistance to
neutralization. Plasma samples from 16 macaques chronically
infected with SIVmac239 were titered for neutralization of each
strain (A). SIVmac251NE and SIVmac251UCD are both more
resistant to neutralization by plasma than SIVmac251TCLA (2-
tailed Wilcoxon matched pairs tests, P = 0.0006). SIVmac251UCD is
more resistant to neutralization by plasma than SIVmac251NE (2-
tailed Wilcoxon matched pairs test, P = 0.0098). SIVmac251NE,
SIVmac251UCD, SIVmac251TCLA were also compared for their
sensitivity to neutralization by a soluble CD4 protein, sCD4-IgG,
which consists of human CD4 domains 1 and 2 fused to the IgG1
heavy chain (B). The dashed line indicates 50% of maximal
infectivity.
(TIFF)
Table S1 Significance of differences among animals
infected versus uninfected after SIVmac251UCD chal-
lenge. Differences among infected versus uninfected animals in
peak SIVmac239Dnef viral loads, total SIVmac239Dnef replication
(estimated from AUC values for log10 RNA copies per ml6weeks),
gp120 ELISA titers, gp140 ELISA titers, 50% ADCC titers, and
AUC values for ADCC were evaluated for significance by 2-tailed
Mann-Whitney U tests. Significance was not determined (ND) for
comparisons that included less than 3 animals in one group.
(DOCX)
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